The effect of Gankang Suppository on duck hepatitis B virus, serum biochemistry and liver histology in ducklings

Journal of Huazhong University of Science and Technology - Medical Science

Volumn 28, Issue 4, 2008, Pages 421-425

  Li, Hui ^a   Tian, Deying ^a   Wu, Huiling ^a   Chen, Miao ^a   Chen, Anqun ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Animal model; Biochemistry; Duck hepatitis; Duck hepatitis B virus; Gankang Suppository; Histology

Indexed keywords

ACICLOVIR; ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; GAN KANG; GAN-KANG; GLYCYRRHIZIC ACID; HERBACEOUS AGENT; LENTINAN;

ANIMAL; ANIMAL DISEASE; ANIMAL HEPATITIS; ARTICLE; BLOOD; DRUG EFFECT; DUCK; DUCK HEPATITIS B VIRUS; HEPADNAVIRUS INFECTION; LIVER; PATHOLOGY; SUPPOSITORY; VIRUS REPLICATION;

ACYCLOVIR; ALANINE TRANSAMINASE; ANIMALS; ANTIVIRAL AGENTS; ASPARTATE AMINOTRANSFERASES; DRUGS, CHINESE HERBAL; DUCKS; GLYCYRRHIZIC ACID; HEPADNAVIRIDAE INFECTIONS; HEPATITIS B VIRUS, DUCK; HEPATITIS, VIRAL, ANIMAL; LENTINAN; LIVER; SUPPOSITORIES; VIRUS REPLICATION;

EID: 49749122590     PISSN: 16720733     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11596-008-0410-4     Document Type: Article

References (19)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepatitis, 2004,11(2):97-102
2. World Health Organization. Hepatitis B. World Health Organization Fact Sheet 204 (Revised October 2000). WHO Web site. 2000 http://who.int/inf-fs/en/ fact204.html
3. Lok A S. Chronic hepatitis B. N Engl J Med, 2002,346(22):1682-1683
4. Yang D F, Tian D Y, Shen H X. The Effects and side effects of suppository Gankang on chronic HBV infection. Chin J Integr Tradit West Med Liver Dis (Chinese), 2002, 12(5):270-271
5. Bieche I, Olivi M, Champeme M H et al. Novel approach to quantitative polymerase chain reaction using real time detection: application to the detection of gene amplification in breast cancer. Int J Cancer, 1998,78(5):661-666
6. Lian Y X, Tan J, Deng Z D et al. Experimental study of shuangcao granule no. 1 on duck hepatitis B virus in ducklings. Chin J Integr Tradit West Med (Chinese), 2000, 20(7):530-532
7. Shead A, Vickery K, Pajkos A et al. Effects of phyllanthus plant extracts on duck hepatitis B virus in vitro and in vivo. Antiviral Res, 1992,18(2):127-138
8. Wen Y M. Study and application of therapeutic vaccine in Hepatitis B. Chin J Infect Dis (Chinese), 1996,149(3): 159-161
9. Cao H, Tao P. Anti-hepatitis B virus effects of lamivudine and other five drugs in vitro. Chin Med J (Chinese), 2001,81(16):1004-1007
10. Hantz O, Périgaud C, Borel C et al. The SATE pronucleotide approach applied to acyclovir: part II. Effects of bis (SATE) phosphotriester derivatives of acyclovir on duck hepatitis B virus replication in vitro and in vivo. Antiviral Res, 1999,40(3):179-187
11. Chen Y, Guo S, Qi Z et al. Experimental study on the effect of combination therapy with lamivudine and famciclovir against duck hepatitis B virus in vivo. Chin J Hepatol (Chinese), 2001,9(4):209-211
12. Zhang D F. Novel therapeutic strategies based on mechanism of clearance of HBV in body. Chin J Hepatol (Chinese), 2001,9(4):196-202
13. Zeng J, Tian D Y, Yang D F et al. Inhibitory effects in vitro of Gankang suppository on hepatitis B virus. Chin J Integr Tradit West Med Liver Dis (Chinese), 2004,14(1):39-41
14. Guidotti L G, Ando K, Hobbs M V et al. Cytotoxic T lymphocytes inhibits hepatitis B virus gene expression by a non-cytolytic mechanism in transgenic mice. Proc Natl Acad Sci USA, 1994,91:3764-3768
15. Webster G J, Reignat S, Maini M K et al. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology, 2000,32(5):1117-1124
16. Guidotti L G, Rocheford R, Chung L et al. Viral clearance without destruction of infected cells during acute HBV infection. Science, 1999,284(5415):825-829
17. Kroes B H, Beukelman C J, Vandenberg A J et al. Inhibition of human complement by β-glycyrrhetinic acid. Immunology, 1997,90(1):115-120
18. Kumada H. Long-term treatment of chronic hepatitis C with glycyrrhizin [Stronger Neo-Mimophagen C (SNMC)] for preventing liver cirrhosis and hepatocellular carcinoma. Oncology, 2002,62(Suppl 1):94-100
19. Fujisawa Y, Sakamoto M, Matsushita M et al. Gly-cyrrhizin inhibits the lytic pathway of complement - possible mechanism of its anti-inflammatory effect on liver cells in viral hepatitis. Microbiol Immunol, 2000, 44(9):799-804